Abstract
We present a review of the literature on dopamine receptor agonists along with our own data on the treatment of Parkinson’s disease (PD) with Mirapex, which was used in 30 patients (mean age 61.8 ± 7.7 years, duration of disease 8.4 ± 1.3 years). Mirapex was used at a dose of 3.5 ± 1.1 mg/day on the background of treatment with levodopa preparations. The efficacy of Mirapex was assessed using quantitative scales. Improvements were demonstrated in general state, motor activity, daily activities, and the quality of life. Attention is drawn to a decrease in the severity of motor fluctuations and dyskinesias and in anxiety and depression, and to improvements in cognitive functions. The significance of the combination of the high efficacy and good tolerance of this agent is emphasized.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson’s Disease and Parkinsonism Syndrome [in Russian], MEDpress, Moscow (1999).
M. R. Nodel’, D. V. Artem’ev, and N. N. Yakhno, “The efficacy of the dopamine agonist Mirapex in Parkinson’s disease,” Nevrol. Zh., 4, 45–49 (1999).
N. V. Fedorova and V. N. Shtok, “Strategy and tactics in the treatment of Parkinson’s disease,” Konsilium, 3, No. 5, 237–242 (2001).
V. N. Shtok and N. V. Fedorova, The Treatment of Parkinsonism [in Russian], Moscow (1997).
V. N. Shtok and N. V. Fedorova, “Current concepts in the treatment of parkinsonism,” Rus. Med. Zh., 6, No. 13, 837–844 (1998).
N. N. Yakhno, “Current approaches to the treatment of Parkinson’s disease,” Klin. Farmakol. Ter. No. 3–4, 92–97 (1994).
P. Carvey, S. Pieri, and Z. Ling, “Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole,” J. Neural Transm., 104, 209–228 (1997).
J. M. Cedarbaum, “Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson’s disease,” Neurol. Clin., 8, 31–49 (1990).
T. N. Chase and J. F. Oh, “Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications,” Ann. Neurol., 47,Supplement 1, 122–129 (2000).
G. Cohen, “Oxygen radicals and Parkinson’s disease,” in: Oxygen Radicals and Tissue Injury. B. Halliwell (ed.) (1988), pp. 130–135.
M. C. Caldwell, I. Boyfield, T. Brown, et al., “Comparison of the functional potencies of ropinerole and other dopamine receptor agonists at human D2 (long), D3 and D4 receptors expressed in Chinese hamster ovary cells,” Brit. J. Pharmacol., 127, No. 7, 1696–1702 (1999).
M. H. Corrigan, A. Q. Denahan, C. E. Wright, and R. J. Ragual, “Comparison of pramipexole, fluoxetine, and placebo in patients with major depression,” Depress. Anxiety, 11, 58–65 (2000).
S. Fahn, “Adverse effects of levodopa,” in: The Scientific Basis for the Treatment of Parkinson’s Disease, C. W. Olanow and A. N. Lieberman (eds.), Carnforth, UK (1992), pp. 89–112.
S. T. Gancher, “Pharmacology of Parkinson’s disease,” in: Parkinson’s Disease, S. J. Huber and J. L. Cummings (eds.), New York (1992), pp. 273–287.
C. G. Goetz, “Dopaminergic agonists in the treatment of Parkinson’s disease,” Neurology, 40,Supplement 3, 50–54 (1990).
M. Guttman, “Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease,” Neurology, 49,Supplement 4, 1060–1065 (1997).
R. G. Holloway, “The Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson’s disease: a four-year randomized controlled trial,” Neurology, 58, 81–82 (2000).
J. P. Hubble, W. C. Koller, N. R. Cutler, et al., “Pramipexole in patients with early Parkinson’s disease,” Clin. Neuropharmacol., 18, No. 4, 338–347 (1995).
M. Kreider and S. Knox, “A multicenter double-blind study of ropinirole as an adjunct to l-dopa in Parkinson’s disease [abstract],” Neurology, 46,Supplement, 475 (1996).
A. E. Lang, “Are the new dopamine agonists better than the old ones?” in: Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona (2000).
A. Lieberman, S. Imke, M. Muenter, et al., “Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’s disease patients with fluctuating responses to levodopa/carbidopa,” Neurology, 43, 1981–1984 (1993).
A. Lieberman, A. Ranhosky, and D. Korts, “Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study,” Neurology, 49, No. 1, 162–168 (1997).
G. Linazasoro, “On behalf of Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to pramipexole,” J. Neurol., 251, 335–339 (2004).
C. D. Marsden, “The mysteries of motor function of the basal ganglia: the Robert Wartenburg lecture,” Neurology, 32, 514–539 (1982).
C. D. Marsden, “Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 57, 672–681 (1994).
E. S. Molho, S. A. Factor, W. J. Weiner, et al., “The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson’s disease,” J. Neural. Transm., 45,Supplement, 225–230 (1995).
D. Nyholm, H. Lennernas, C. Trolin, et al., “Plasma levodopa concentrations in parkinsonian patients during activities of daily living,” in: The Movement Disorder Society’s 6th International Congress of Parkinson’s Disease and Movement Disorders, Barcelona (2000).
N. Ogawa, I. Miyazaki, K. Tanaka, et al., “Dopamine D2 receptor mediated antioxidant and neuroprotective effects of ropinirole,” in: XIII International Congress on Parkinson’s Disease, Vancouver (1999).
C. W. Olanow, “Oxidation reactions in Parkinson’s disease,” Neurology, 40Supplement 3, 32–37 (1990).
C. W. Olanow, “A rationale for dopamine agonists as primary therapy for Parkinson’s disease,” Can. J. Neurol. Sci., 19, 108–112 (1992).
J. D. Parkes, N. Schachter, C. D. Marsden, et al., “Lisuride in parkinsonism,” Ann. Neurol., 9, 48–52 (1981).
“Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism,” Neurology, 55, 1540 (2000).
“Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD study,” J. Clin. Neuropharmacol., 23, No. 1, 34–44 (2000).
H. L. Paulson and M. B. Stern, Movement Disorders: Neurologic Principles and Practice, New York (1997), pp. 183–199.
M. F. Piercey, W. E. Hoffmann, M. W. Smith, et al., “Inhibition of dopamine neuron firing by pramipexole, a dopamine D, receptor-preferring agonist: comparison to other dopamine receptor agonists,” Eur. J. Pharmacol., 312, No. 1, 35–44 (1996).
M. M. Pinter, O. Pogarell, and W. H. Ortel, “Efficacy, safety and tolerance of non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double-blind, placebo controlled, randomized, multicentre study,” J. Neurol. Neurosurg. Psychiat., 66, No. 4, 436–441 (1999).
W. H. Poewe and G. K. Kenning, “The natural history of Parkinson’s disease,” Ann. Neurol., 44,Supplement 1, 1–9 (1998).
O. Pogarell, T. Gasser, J. J. van Hilten, et al., “Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomized double-blind, placebo controlled, multicentre study,” J. Neurol. Neurosurg. Psychiat., 72, No. 6, 713–720 (2002).
R. M. Post, R. H. Gerner, J. S. Carman, et al., “Effects of dopamine agonist piribedil in depressed patients: relationship of pre-treatment homovanillic acid to antidepressant response,” Arch. Gen. Psychiat., 35, No. 5, 609–615 (1978).
N. Quinn, “Drug treatment of Parkinson’s disease,” Brit. Med. J., 310,Supplement 6979, 575–579 (1995).
A. H. Rajput, “Adverse effects of ergot-derivative dopamine agonists,” in: Dopamine Agonists in Early Parkinson’s Disease, C. W. Olanow and J. E. Obeso (eds.), Kent, UK (1997), pp. 209–216.
O. A. Rascol, “A double blind l-dopa controlled study of ropinirole patients with early Parkinson’s disease,” Neurology, 46,Supplement, 139 (1996).
H. Reichmann, H. M. Brecht, P. J. Kraus, et al., “Pramipexole in Parkinson’s disease. Results of a treatment observation,” Nervenarzt, 73, No. 8, 745–750 (2002).
U. K. Rinne, “Early dopamine agonist treatment in Parkinson’s disease,” in: Parkinson’s Disease: the Role of Dopamine Agonists, A. Lieberman and X. Lataste (eds.), Lanes (1989), pp. 29–33.
U. K. Rinne, “A five year double blind study with cabergoline versus levodopa in the treatment of early Parkinson’s disease,” in: XIII International Congress on Parkinson’s Disease, Vancouver (1999).
F. Sautel, N. Griffon, D. Levesque, et al., “A functional test identifies dopamine agonists selective for D3 versus D2 receptors,” NeuroReport, 6, No. 2, 329–332 (1995).
M. Schroder, A. Kühn, and A. Kupsch, “Impaired tonic vigilance associated with pramipexole,” in: Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona (2000).
K. M. Shannon, J. P. Bennett, and J. H. Friedman, “Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group,” Neurology, 49, No. 724–728 (1997).
R. P. Snaith, M. Hamilton, S. Morley, et al., “A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale,” Brit. J. Psychiat., 167, No. 1, 99–103 (1995).
W. G. Tatton, W. Y. H. Ju, J. Wadia, et al., “Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy,” in: Neurodegeneration and Neuroprotection in Parkinson’s Disease, C. W. Olanow, P. Jenner, and M. H. B. Youim (eds.), London (1996), pp. 202–220.
“The Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson’s disease. A randomized dose-ranging study,” J. Am. Med. Assoc., 278, No. 2, 125–130 (1997).
“The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial,” J. Am. Med. Assoc., 284, No. 15, 1931–1938 (2000).
J. Waehrens and J. Gerlach, “Bromocriptine and imipramine in endogenous depression: a double-blind controlled trial in out-patients,” J. Affect. Disord., 3, No. 2, 193–202 (1981).
W. J. Wiener and A. E. Lang, Movement Disorders: a Comprehensive Survey, Mount. Kisco, New York (1989).
L. Wermuth, “A double-blind, placebo-controlled, randomized, multicenter study of pramipexole in advanced Parkinson’s disease,” Eur. J. Neurol., 5, No. 3, 235–242 (1998).
E. C. Wolters, G. Tissingh, P. L. M. Bergmans, et al., “Dopamine agonists in Parkinson’s disease,” Neurology, 45,Supplement 3, 28–34 (1995).
G. F. Wooten, “Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson’s disease,” Ann. Neurol., 24, 363–365 (1988).
A. Zenzola, C. Diroma, A. Fraddosio, et al., Efficacy and Tolerability of Dopamine Agonists in a Parkinsonian Population, Bar (2000).
M. Ziegler and P. Rondor, “Activity of piribedil in Parkinson’s disease: a multicenter study,” Presse Med., 28, 1414–1418 (1999).
Author information
Authors and Affiliations
Additional information
__________
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 106, No. 6, pp. 26–33, June, 2006.
Rights and permissions
About this article
Cite this article
Fedorova, N.V., Chigir’, I.P. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson’s disease. Neurosci Behav Physiol 37, 539–546 (2007). https://doi.org/10.1007/s11055-007-0050-3
Received:
Issue Date:
DOI: https://doi.org/10.1007/s11055-007-0050-3